Encorafenib plus cetuximab not recommended for previously treated colorectal cancer
Although it meets NICE’s criteria for being a life-extending treatment, the cost-effectiveness estimates are higher than what is normally considered a cost-effective use of NHS resources.
Published
Please sign in or register for FREE
Sign in to OnMedica
Or sign in via
Are you a GP or Specialist Doctor, practising in UK, looking for:
- easy-to-digest, relevant updates and educational content
- a safe-space to share and collaborate with peers?
OnMedica is for you, sign up FOR FREE now!
No comments yet.